AzTrials
AzTrials

Erectile Dysfunction Following Radical ProstatectomyNCT06200987

Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy

A study testing Penile vibrator in people with Erectile Dysfunction Following Radical Prostatectomy and Incontinence, run by Herlev and Gentofte Hospital at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Penile vibrator
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteDenmark
Study dates
1 Feb 2024to Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men who are undergoing nerve-sparing radical prostatectomy
  • Pre operative erectile function of IIEF-EF > 25
  • Sexually active . Continent before surgery defined as a score of 0 on the ICIQ-SF questionnaire

Who cannot join

  • Urinary incontinent before surgery
  • Comorbidity that prevents the patient from taking PDE5-inhibitors
  • Disease in the penis or in the penile skin (Peyronies, phimosis)
  • Problems using the vibrator ie impaired function of the hands

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Helene R Andersen, MD contact

+4538681507

helene.reif.andersen@regionh.dk

Denmark1 site, 1 recruiting
  • Herlev and Gentofte Hospital

    Herlev, 2730

    Mette LK Schmidt, PHD, +4538681100, Mette.Ladefoged.Kopp.Schmidt@regionh.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Planned Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy: a Randomized Controlled Study

To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the "Ferticare 2.0" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.

Both groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, "neglected side effects" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).

The collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.

Read the detailed description

Hypothesis The study's hypothesis is that vibration therapy, using the stimulation parameters found in the pilot study, will have a beneficial effect on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity.

Methods The study is conducted as a randomized, controlled non-blinded study. Men undergoing a nerve-sparing operation for prostate cancer are divided into two groups. A total of 100 men will be included in the study. In case a surgery cannot be performed with nerve preservation or if a participant experiences a recurrence of their prostate cancer requiring additional treatment, the participant will be withdrawn from the study.

Randomization and Treatment Overall, we will investigate the effect of vibration stimulation on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity. In accordance with the hypotheses, this study will offer vibration therapy for a longer duration than before. Both the vibration group and the control group will be offered fixed post-operative treatment with phosphodiesterase-5-inhibitors as per the standard protocol. Participants will be randomized into the two groups through drawing lots for either vibration or no vibration. Randomization will be done using block randomization via a computer-generated list. The "Ferticare 2.0" vibrator (produced by the company Reflexonic LLC, Leesburg VA, USA) will be used in the study, which is a modernized version of the previously used vibrator and is sold as a sexual aid in Denmark. It is safety-approved with European CE marking as a "household appliance" and is sold as a sexual aid in Denmark. Men in the vibration group will be instructed on the stimulation before their prostate surgery. Subsequently, participants will be able to perform the vibration therapy themselves at home. In both groups, participants must undergo a standard pelvic floor training program, and both groups will be offered fixed PDE-5 inhibitor treatment in the form of daily tadalafil, 5 mg, as the standard treatment for erectile difficulties after the operation. In the vibration group, daily stimulation will be directed towards the frenulum for a minimum of 5 minutes, with an amplitude of 1 mm and a frequency of 90 Hz, as found in the pilot study. Participants will start getting used to the vibration 1-4 weeks before the surgery and resume it within 14 days after the operation. The daily stimulation will continue for a period of 9 months, along with the standard treatment. After these 9 months, men in both groups will stop taking tadalafil during a 4-week wash-out period, after which their spontaneous sexual function will be evaluated. This is necessary due to the well-known positive effect of the medication. In comparison to the standard treatment in the department, offering vibration to half of the participants is an addition. Regarding pelvic floor training and medication for erectile difficulties for all study participants, the current standard is to offer these to all men who have undergone nerve-sparing radical prostatectomy. This will proceed as usual, and the only deviation from usual practice is ensuring that the medication offer is consistent for all participants. The mentioned 4-week period without tablet treatment (wash-out) is necessary to assess spontaneous erections. This is a deviation from the normal standard, as such a wash-out is not conducted for patients who do not participate in research, but it will not affect the actual erectile function of the participants in either group.

Data Collection

Standard investigations related to prostate cancer will be conducted according to normal guidelines, with the registration of:

  • Pre-operative PSA
  • Clinical and pathological tumor stage
  • Gleason score
  • Prostate size
  • Degree of nerve preservation during the surgery
  • Any complications during the surgery
  • Resection margin status (positive or negative)
  • PSA measurements at 3, 6, and 12 months after the operation. This information will be obtained from the patient's medical records by the scientific staff after the study participants have given their consent to participate. After providing consent, the study organizers, sponsor, sponsor's representatives, and any regulatory authorities will have direct access to obtain information from the patient's medical records, including electronic records, for the purpose of reviewing information about the research participant's health, as necessary for conducting the research project and for monitoring, including self-monitoring, quality control, and oversight, as they are obligated to perform.

Since potential participants are screened and informed about the project during their visits to the outpatient clinic (see the section on Recruitment of Study Participants and Informed Consent), there is no need to obtain information from the patient's medical records before consent is given. At this stage, the research team only receives the name, social security number, and contact information for patients who have expressed interest in the project.

Additional examinations are carried out before the surgery and at follow-ups at 3 months, 6 months, and 10 months (equivalent to the end of the wash-out period) after the surgery, with the registration of the following for all participants in both the vibration group and the control group:

Before the surgery and at follow-ups:

  • Validated symptom questionnaires for erectile function (IIEF-EF and EHS)
  • Specific questionnaire about orgasm disturbances, penile shortening, and urinary incontinence during sexual activity.
  • Validated symptom questionnaire for incontinence symptoms (ICIQ-SF)
  • 24-hour pad weighing test (only at follow-ups for men who are not fully continent)

Additional registrations at follow-ups:

  • Registration of PSA recurrence after the surgery and noting any additional treatment
  • Any side effects of vibration and standard treatment
Being tested
Penile vibrator

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Penile vibratorDevice

    In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months

Study groups in NCT06200987
Study groupRoleWhat they receive
InterventionExperimentalThe group randomized to use the vibrator for 9 months
Receives: Device: Penile vibrator
ControlsNo interventionUsual standard treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Erectile function

    The erectile function compared to controls measured by IIEF-EF

    Measured: 10 months

Secondary outcomes (6)
  1. ICIQ-UI-SF: The International Consultation on Incontinence Questionnaire - Urinary Incontinence - short form

    Difference in ICIQ-SF score between the two groups after 3, 6 and 10 months. The score is from 0-21. The higher the score the more incontinent. A score of 0 is no urinary incontinence.

    Measured: 10 months

  2. IIEF-EF score (The International Index of Erectile Function - Erectile Function)

    Difference in IIEF-EF score between the two groups after 3, 6 and 10 months. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.

    Measured: 10 months

  3. Diaper weighing test

    Difference in 24 hour diaper weighing test between the two groups after 3, 6 and 10 months

    Measured: 10 months

  4. IIEF-EF (The International Index of Erectile Function - Erectile Function) over 25

    The percentage of patients who gain a post-operative spontaneous IIEF-EF score of at least 25. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.

    Measured: 10 months

  5. EHS (Erection Hardness Scale)

    The percentage of patients who gain a post-operative spontaneous EHS of at least 3. The scale is from 0-4. 0 is no erection, the higher the score the better erection.

    Measured: 10 months

  6. Neglected sexual side effects

    The presence of orgasm disturbances, penile shortening and urinary incontinence in relation to sexual activity.

    Measured: 10 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2024
  2. Study start1 Feb 2024
  3. Primary completionMar 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06200987
Sponsor's protocol ID
ProVibrate
Status last verified
Mar 2024
First submitted
29 Dec 2023
Last updated
12 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Available upon request. Subject to approval from the Danish Data Protection Agency.

Questions about this trial

What is this clinical trial studying?

A study testing Penile vibrator in people with Erectile Dysfunction Following Radical Prostatectomy and Incontinence, run by Herlev and Gentofte Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Helene R Andersen, MD (+4538681507, helene.reif.andersen@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Erectile function (time frame: 10 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2024; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in